907 related articles for article (PubMed ID: 27887655)
1. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Sato M; Ye W; Sugihara T; Isaka Y
BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
[TBL] [Abstract][Full Text] [Related]
2. Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.
Tanaka S; Yamamoto T; Oda E; Nakamura M; Fujiwara S
J Bone Miner Metab; 2018 Jan; 36(1):87-94. PubMed ID: 28028633
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review.
Fujiwara S; Miyauchi A; Hamaya E; Nicholls RJ; Weston A; Baidya S; Pinto L; Barron R; Takada J
Arch Osteoporos; 2018 Mar; 13(1):34. PubMed ID: 29564555
[TBL] [Abstract][Full Text] [Related]
4. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
Modi A; Siris ES; Tang J; Sen S
Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients.
Goldshtein I; Nguyen AM; dePapp AE; Ish-Shalom S; Chandler JM; Chodick G; Shalev V
Arch Osteoporos; 2018 Mar; 13(1):15. PubMed ID: 29502187
[TBL] [Abstract][Full Text] [Related]
6. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y; Sone T; Tanaka S; Miyazaki T; Tsukiyama M; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
[TBL] [Abstract][Full Text] [Related]
7. Age- and gender-specific epidemiology, treatment patterns, and economic burden of osteoporosis and associated fracture in Taiwan between 2009 and 2013.
Wang CY; Fu SH; Yang RS; Shen LJ; Wu FL; Hsiao FY
Arch Osteoporos; 2017 Oct; 12(1):92. PubMed ID: 29067572
[TBL] [Abstract][Full Text] [Related]
8. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
[TBL] [Abstract][Full Text] [Related]
9. Disparities in osteoporosis treatments.
Liu Z; Weaver J; de Papp A; Li Z; Martin J; Allen K; Hui S; Imel EA
Osteoporos Int; 2016 Feb; 27(2):509-19. PubMed ID: 26216226
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Lin TC; Yang CY; Kao Yang YH; Lin SJ
Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
[TBL] [Abstract][Full Text] [Related]
12. Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012-2015.
Tamaki J; Fujimori K; Ikehara S; Kamiya K; Nakatoh S; Okimoto N; Ogawa S; Ishii S; Iki M;
Osteoporos Int; 2019 May; 30(5):975-983. PubMed ID: 30648192
[TBL] [Abstract][Full Text] [Related]
13. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
[TBL] [Abstract][Full Text] [Related]
14. Cost and management of males with closed fractures.
Brenneman SK; Yurgin N; Fan Y
Osteoporos Int; 2013 Mar; 24(3):825-33. PubMed ID: 22776864
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
16. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
Kim K; Svedbom A; Luo X; Sutradhar S; Kanis JA
Osteoporos Int; 2014 Jan; 25(1):325-37. PubMed ID: 24114398
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates.
Foster SA; Foley KA; Meadows ES; Johnston JA; Wang S; Pohl GM; Long SR
BMC Womens Health; 2008 Dec; 8():24. PubMed ID: 19105828
[TBL] [Abstract][Full Text] [Related]
18. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.
Viswanathan HN; Curtis JR; Yu J; White J; Stolshek BS; Merinar C; Balasubramanian A; Kallich JD; Adams JL; Wade SW
Appl Health Econ Health Policy; 2012 May; 10(3):163-73. PubMed ID: 22510025
[TBL] [Abstract][Full Text] [Related]
19. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
[TBL] [Abstract][Full Text] [Related]
20. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
